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ABSTRACT 
 Late SV40 factor (LSF) is a CP2 family transcription factor involved in cell cycle 
regulation. In liver cancer, LSF is an oncogene, in part due to its role in upregulation of 
osteopontin leading to increase tumor size. As a result, LSF is a potential target for drug 
discovery. LSF binds the p65 subunit of the transcription factor NFκB and also the 
transcription factor ying yang 1 (YY1). In this thesis, I show that binding of both YY1 
and p65 occurs at the ubiquitin-like domain of LSF in U2OS cell extracts. Interestingly, 
when phosphatase inhibitors are added during preparation of U2OS cell extracts, the 
binding of YY1 and p65 to LSF shifts from the ubiquitin-like domain of LSF to the DNA 
binding domain. The role of a yet unidentified docking protein may be responsible for 
this shift in binding.  In an attempt to map the specific region of the LSF sequence that is 
involved in these interactions, I have developed a peptide identification assay which 
utilizes protease digestion, protein mediated peptide capture, and LC ESI-MS. Through 
the use of this assay, I’m confident that the sequence(s) involved in these LSF protein-
protein interactions can be further defined. 
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Introduction 
 Late SV40 factor (LSF) is a CCAAT-binding protein 2 (CP2) family transcription 
factor responsible for stable progression through the G1/S transition of the cell cycle 
(Santhekadur et al. 2012). It is known to bind the SV40 promoter, for which it is named 
(Santhekadur et al. 2012), as well as to repress the interleukin-2 (IL-2) promoter 
(Traylor-Knowles et al., 2010). LSF also binds the promoters of the α, β, and γ-globin 
genes, uroporphyrinogen III synthase, transferrin, IL4, serum amyloid A3, pax6, and 
osteopontin genes (Santhekadur et al., 2012). LSF directly upregulates osteopontin in the 
development of hepatocellular carcinoma (HCC)(Yoo et al. 2010) and as a result, causes 
an increase in tumor size (Yoo et al. 2010). HCC is one of the most prevalent forms of 
liver cancer worldwide and kills more than 600,000 people each year (Ferenci et al. 
2010) making LSF a potentially important target for drug discovery. Importantly, LSF 
binds the thymidylate synthase (TS) promoter allowing TS gene expression. TS is the rate 
limiting enzyme for deoxythymidine triphosphate synthesis (Santhekadur et al. 2012) and 
as such, it plays an essential role in the regulation of S-phase in the cell cycle 
(Santhekadur et al. 2012). Limited deoxyribonucleotide concentrations can trigger cell 
cycle arrest leading to apoptosis (Santhekadur et al. 2012). LSF cell cycle activity is 
regulated by phosphorylation by ERK and Cyclin C/ Cdk2 during G1 (Santhekadur et al. 
2012). Phosphorylation at serine 291 by ERK and at serine 309 by Cyclin C/ Cdk2 
inhibits the transcriptional activity of LSF while subsequent dephosphorylation 
reactivates it (Santhekadur et al. 2012).  
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Structurally, LSF is predicted to contain a sterile alpha motif (SAM) domain, a 
DNA binding domain, and an ubiquitin-like domain (Kokoszynska et al. 2008). The 
SAM and ubiquitin-like domains appear to be close together in sequence while the DNA 
binding domain is separated from the SAM domain by a 67 amino acid linker region 
(Kokoszynska et al. 2008) (Figure 1b). Though no crystal structure for LSF has yet been 
reported, the identification of the above domains in LSF was determined by homology 
modeling and fold recognition programs through the Structure Prediction Meta Server 
(Kokoszynska et al. 2008). Domain spacing was determined through GlobPlot 
(Kokoszynska et al. 2008). Furthermore, LSF’s DNA binding domain was predicted to 
have a high similarity to the DNA binding domain of p53 (Kokoszynska et al. 2008) 
which contains a combination of α-helixes and β-sheets in a beta-sandwich fold 
(Kokoszynska et al. 2008). Though related to the Grainyhead family of transcription 
factors, LSF diverged from a common ancestor through a gene duplication event 
(Traylor-Knowles et al. 2010). LSF and Grainyhead are both utilized as developemental 
proteins (Traylor-Knowles et al. 2010). However, while LSF is only involved in chicken 
(Murata et al. 1998) and human eye development, through the regulation of PAX6 gene 
expression (Zheng et al. 2001), Grainyhead is required for the development of epithelial 
integrity in mice, Xenopus, Drosophilia, and C. elegans (Traylor-Knowles et al. 2010). 
Grainyhead is also necessary in the development of the central nervous system in mice 
and Drosophilia (Traylor-Knowles et al. 2010). LSF differs structurally from Grainyhead 
in that it contains the SAM domain and the ability to dimerize in solution yet binds DNA 
as a tetramer (Traylor-Knowles et al. 2010). In contrast, Grainyhead can only dimerize 
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and does not bind DNA as a tetramer. Although both LSF and Grainyhead dimerize 
individually and are structurally similar, they don’t dimerize cross-family (Shirra and 
Hansen, 1998). Previous experimental attempts to map the LSF oligomerization domain 
have found that the region responsible for LSF dimerization and tetramerization lies 
between residues 266 and 501 (Shirra and Hansen, 1998). Furthermore, substitution 
mutants between residues 211 and 213 and residues 235 and 237 show decreased 
dimerization compared to wild-type LSF (Shirra et al, 1994. Shirra and Hansen, 1998).  
LSF has been shown to participate in a number of protein-protein interactions 
with partners including YY1, p65, the major transcriptional proteins TBP and TFIIB, 
dinG a homolog of RING1, and Fe65, as described in more detail below. RING1 is a 
Polycomb group protein found in humans and is responsible for binding multiple 
Polycomb group proteins through its RING finger domain (Satjin and Otte, 1999). 
Polycomb group complexes are known to repress transcription though interestingly, when 
RING1 is overexpressed in Rat1a embryonic fibroblast cells, it leads to the 
overexpression of c-myc and subsequent increase in cell proliferation and cell size (Satjin 
and Otte, 1999). LSF interacts with dinG, a homolog of RING1, at dinG’s C-terminus 
(Tuckfield et al. 2002) and this interaction leads to specific repression of the LSF-
dependent α-globulin promoter in human embryonic kidney (HEK 293) cells (Tuckfield 
et al. 2002). Fe65 is a neuronal adaptor protein that binds the integral membrane protein 
APP (β-amyloid precursor protein) which is the precursor for the plaque forming β-
amyloid peptide that is implicated in the pathology of Alzheimer’s disease. Fe65 has been 
shown to interact with LSF in COS7 cells through co-immunoprecipitation experiments 
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between Fe65 and full-length LSF (Bruni et al. 1998). LSF also binds to the transcription 
factor YY1. Binding of YY1 to LSF along with HDAC1 forms the LSF-YY1-HDAC1 
complex. After formation, this complex represses expression from the long terminal 
repeat (LTR) sequence comprising the HIV promoter (Coull et al. 2000). This repression 
causes HIV to enter a latent state allowing the virus to evade the host immune system. 
Inhibition of the LSF-YY1-HDAC1 complex would therefore force existing latent virus 
to continue expression and prevent new virus from entering latency. This would 
potentially allow treatments to combat the viral infection while preventing resurgence of 
the viral population. LSF has also been shown to interact with p65 (RelA) an essential 
component of the NF-κB signaling pathway (Bing et al. 2000). The p65 subunit of the 
p50-p65 heterodimer associates with LSF during cytokine induced activation of the NF-
κB pathway (Bing et al. 2000). 
 YY1 is a zinc-finger transcription factor that is found in all cell types and binds a 
wide range of promoters (Flanagan, 1995). The sequence of YY1 contains four zinc 
finger motifs along with two N-terminal transcriptional activation domains, a glycine rich 
domain, and a C-terminal transcriptional repression domain (Gordon et al. 2006). 
Because it contains both an N-terminal activation domain and a C-terminal repression 
domain, YY1 can repress or stimulate transcription of the promoters it regulates (Gordon 
et al. 2006). Whether YY1 acts as a transcriptional repressor or an activator depends on 
the proteins associating with it (Gordon et al. 2006). The co-crystal structure the C-
terminus domain (Gordon et al. 2006) of YY1 (amino acids 295-408) with a 20 base pair 
oligonucleotide corresponding to the adeno-associated virus p5 initiator element shows 
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that the secondary structure of the protein is made up of four α-helices connected by 
looped regions which are responsible for holding the zinc ions in place forming four zinc 
finger domains (Figure 2) (Houbaviy et al. 1996). All four zinc finger domains bind the 
major groove of DNA and three of the four zinc finger domains make multiple contacts 
with the major groove through interactions with their side chains while the fourth makes 
only a single base contact (Houbaviy et al. 1996). YY1 is implicated in various cellular 
processes including cyclin expression, apoptosis, and histone modification (Gordon et al. 
2006). It has also been shown to associate with p53 and the oncoprotein c-myc (Gordon 
et al. 2006). 
 p65 functions as a transcription factor in the NF-κB pathway and predominantly 
dimerizes with NF-κB protein p50 at the rel homology domain. p65-p50 heterodimers are 
held in an inactive state through complex formation with IκBα. Inactivation of p65-p50 
heterodimer is important in order to prevent nuclear translocation prior to activation of 
the pathway by upstream effectors since constitutive association of the heterodimer with 
the cell’s transcriptional machinery at the promoter site would lead to constant gene 
expression (Dolcet et al. 2005). Following activation of the cell by growth factors, 
cytokines, or other specific extracellular stimuli, IκBα is phosphorylated by the IKKβ 
subunit of the IκB kinase (IKK) complex (Dolcet et al. 2005). Once IκBα is 
phosphorylated, it dissociates from p65-p50 and is degraded by the proteasome, releasing 
the p65-p50 heterodimer to translocate to the nucleus where it alters transcription at 
specific promoter sequences (Dolcet et al. 2005). The structure of p65, as shown in the 
co-crystal structure of the p65-p50 heterodimer with DNA derived from the interferon-β 
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promoter PRDII element, is composed of an α-helix adjacent to a β-sandwich connected 
to a pair of antiparallel β-sheets by a looped linker region (Figure 2) (Escalante et al. 
2002). p65 is organized into an N-terminal rel homology domain which contains (from 
N-terminus to C-terminus) the DNA binding domain, dimerization domain, and nuclear 
localization signal and a C-terminal transactivation domain (Perkins. 2007) (Figure 3). 
The NF-κB pathway plays important roles in the regulation of apoptosis, cell 
proliferation, cell migration, and in the immune response. Because of this, it has been 
associated with tumorigenesis and thus, it is a potential target for cancer therapy (Dolcet 
et al. 2005). 
 The goal of the current work is to map the YY1 and p65 protein-protein binding 
sites of LSF to enable later characterization of binding site properties, as well as binding 
studies and inhibitor design. The results show that binding occurs between p65 and the 
ubiquitin-like domain of LSF in U2OS cell extracts. When phosphatase inhibitors are 
added during preparation of U2OS cell extracts, however, binding is observed to shift 
from the ubiquitin-like domain to the DNA binding domain of LSF and the N-terminus of 
LSF linked to a portion of the DNA binding domain. Because of the overlap between 
these two regions, the interaction between LSF and p65 most likely occurs between 
residues 65 and 103. Similar results were observed with YY1 binding to LSF. 
Furthermore, binding of bacterially expressed, recombinant p65 occurs at the DNA 
binding domain of LSF. A peptide identification assay was developed to determine the 
specific amino acid sequence involved in LSF binding to p65. Three out of five of the 
assay steps were validated and are useable for future experiments.  
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Methods 
GST-LSF DNA construct design. I used the pGEX-5x-1 GST expression plasmid from 
GE Health sciences (GE) for all construct vectors. Inserts corresponding to the LSF DNA 
binding domain and SAM domain were amplified using polymerase chain reaction (PCR) 
from a plasmid containing LSF cDNA (EF1α-LSF). The specific primers were 
engineered to contain restriction sites for BamHI and NotI oriented 5’ to 3’. The DNA 
Binding domain forward primer sequence is 5'-
CCCGGGGGATCCCCCTGCCTTTTCAATATGTGCTTTGTGCT-3' and the reverse 
primer sequence is 5'-
AATGCCGCGGCCGCAGGTGTTCGTTTCTCCATTTTTTCCCTATCCGT-3'. The 
SAM domain forward primer sequence is 5'-
CCCGGGGGATCCCCCCAACCACACCTCAG-3' and the reverse primer sequence is 
5'-AATGCCGCGGCCGCTGGACGCACCATCCGGCC-3'. Both vector DNA and 
amplified inserts were digested separately with 20 units of BamHI and NotI (NEB) in a 
50µL reaction with NEB buffer 3 and according to New England Biolabs’ (NEB) 
restriction digest protocol. 1µL of Temperature Sensitive Alkaline Phosphatase 
(Promega) in a 20µL reaction with 1µg of DNA and 2µL of 10x MULTI-CORE buffer 
(Promega) incubated at 25°C for 5 minutes was used to prevent re-circularization of 
digested vector and was heat inactivated at 74°C for 15 minutes prior to ligation. The 
digested inserts were gel-purified according to the QIAgen Gel Purification Spin Column 
Kit and then ligated into the gel-purified digested vector using 400 units of T4 DNA 
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ligase (NEB) at room temperature for 10 minutes with an insert to vector ratio of 10:1. I 
used sequencing (MWG Operon) and restriction enzyme digestion followed by agarose 
gel separation to determine the inserts were present and in the correct orientation. The 
pGEX1, pGEX2, pGEX3, pGEX4, and full length LSF constructs were generously 
provided by Gene Chin (Hansen lab member). 
 
Expression of GST-LSF protein. GST-LSF constructs were transformed into T7 
Express lysY/Iq competent cells (NEB) according to the provided protocol. The competent 
cell aliquots were thawed on ice for 10 minutes prior to transformation. Then, 1 µL of 
ligation mixture was added directly to the competent cells and they were subsequently 
mixed lightly by flicking the base of the tube. The competent cells were incubated on ice 
for 30 minutes before being rapidly heat shocked at 42°C for 20 seconds and then 
incubated on ice for 5 minutes. The cells were then placed in 950 µL of Super Optimal 
broth with Catabolite repression (SOC) media and incubated for 1 hour at 37°C before 
being plated on ampicillin LB agar plates overnight. Cultures were grown from glycerol 
stocks in 2xYT broth with 100 µg/mL of ampicillin at 37°C for 4 hours. The culture was 
then diluted 1:1 and incubated at room temperature for 16 hours in the presence of 100 
µg/mL ampicillin and 0.5 mM IPTG. Cells were centrifuged at 4250xg at 4°C for 10 
minutes and resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 50 mM EDTA, 15% 
glucose, and 2 mM DTT) at a ratio of 33.5 mL of buffer for 500 mL of culture. The cell 
suspension was then incubated with 20 mg/mL of lysozyme for 20 minutes at 4°C before 
being mixed with lysing solution (10 mM Tris-HCl pH 8.0, 50 mM EDTA, and 1% 
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IGEPAL) at one fourth the volume of the lysis buffer for 20 minutes at 4°C. The solution 
was passed through a needle four times, centrifuged for 5 minutes at 18,000xg at 4°C, 
and the supernatant was aliquoted, flash frozen in liquid nitrogen, and stored at -80°C. 
For extended use, the protein can be mixed with 50% glycerol and 0.01% sodium azide 
and stored at -20°C to limit repeated freeze-thaw cycles. Protein amount was quantified 
by Bradford Assay and 10% SDS-PAGE separation. Purity was determined by 10% SDS-
PAGE separation. Protocol yields for individual constructs per 2 mL culture volumes are 
as follows: GST-DBD yields 250 ng, GST-SAM yields 500 ng, pGEX4 yields 500 ng, 
pGEX1 yields 250 ng, pGEX2 yields 250 ng, pGEX3 yields 167 ng, and GST-LSF yields 
50 ng. 
 
GST-LSF binding assay. Studies were performed with the U2OS mammalian 
osteosarcoma cell lines. U2OS cells were grown in DMEM media with 10% fetal bovine 
serum at 37°C with 5% CO2 to 90% confluency, washed with ice cold 1xPBS twice, and 
collected in a 1.5 mL microcentrifuge tube by scraping the dish with a cell scraper after 
the addition of 1mL ice cold 1x Phosphate Buffered Saline (PBS) per 100 mm diameter 
tissue culture dish. The cells were then pelleted by centrifugation at 5,000xg for 2 
minutes. The supernatant was removed and the pellet resuspended in 500 µL of 50 mM 
HEPES pH 7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, and 1% Triton X-100; 
Phosphatase Inhibitor Cocktail IV (Calbiochem) was added here for phosphatase 
inhibitor experiments. The cells were then centrifuged at 20,000xg at 4°C for 10 minutes 
and the supernatant was transferred to a fresh 1.5 mL microcentrifuge tube. The 
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supernatant then was either directly used in the GST-LSF binding assay or stored at 80°C 
after flash freezing in liquid nitrogen. The GST-LSF bacterial lysate (corresponding to 
500 ng of bacterial lysate) was incubated with 20 µL of glutathione Sepharose 4B bead 
resin (GE Healthcare) in a 50% slurry with 1xPBS for 30 minutes at room temperature 
under constant rotation. In order to remove non-specific binding proteins, the beads were 
centrifuged at 500xg for 5 minutes and the supernatant was removed and replaced with 
100 µL of 1xPBS; this was repeated two additional times. The bacterial lysate 
immobilized on bead resin was then added to 300 µL of U2OS cell extract and incubated 
for 1 hour at 4°C under constant rotation. The beads were washed again with 1xPBS 
three times and centrifuged at 500xg for 5 minutes per each wash. The beads were 
incubated with 50 mM Tris-HCl pH 8.0, 10 mM reduced glutathione for 5 minutes at 
room temperature before being centrifuged at 500xg for 5 minutes. The used beads were 
discarded and the supernatant was kept. For phosphatase inhibitor studies, the 
phosphatase inhibitor cocktail used was Phosphatase Inhibitor Cocktail IV (Calbiochem). 
Phosphatase inhibitor cocktail working dilution was 1:100. 
 
Western blot of GST-LSF binding proteins. 10 µL of the GST-LSF binding assay 
samples were electrophoresed through a discontinuous 10% SDS-PAGE mini-gel. The 
4% acrylamide stacking gel and the 10% acrylamide running gel was made with Protogel 
premixed 37.5:1 acrylamide to bisacrylamide (National Diagnostics). For a single gel, the 
electrophoresis conditions were constant amps at 0.01 Amps for the stacking gel and 0.02 
Amps for the running gel. The gel was electrophoresced until the dye front reached the 
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bottom of the mini-gel; this on average correlated into 30 minutes for the stacking gel and 
1 hour for the running gel. The dye used was diluted from a 6x concentrated stock and 
contained dithiothreitol (DTT), 2-mercaptoethanol, bromophenol blue, sodium dodecyl 
sulfate (SDS), and 0.75 M Tris-Glycine buffer pH 6.8 (6x specification). The SDS-PAGE 
gel was then transferred to a methanol-activated PVDF membrane (GE Healthcare) in a 
wet sandwich containing the gel, filter paper, padding, and the membrane overnight at 25 
V in an electrophoresis apparatus filled with Tris-glycine transfer buffer and 10% 
methanol at 4°C. The membrane was blocked with 5% milk in 1xTris buffered saline 
solution with 0.1% Tween-20 (TBST) for 1 hour at room temperature and then washed 
three times, ten minutes each, and under constant rotation with 1xTBST. The membrane 
was then blotted with either 1:100 of α-YY1 (Pierce; product number: PA5 - 12206) or 
1:500 α-p65 (Pierce; product number: PA5 - 16545) for 1 hour in 5 mL of 5% milk 
1xTBST in a heat sealable bag under constant rotation at room temperature. The 
membrane was then washed three times with 1xTBST for 10 minutes each before being 
blotted with 1:5000 of goat anti-rabbit conjugated IgG-HRP secondary (Santa Cruz 
Biotech; Product number: sc-2004) in 50 mL of 5% milk 1xTBST under constant rotation 
at room temperature. The membrane was then washed three times with 1xTBST for 10 
minutes each and then incubated for 2 minutes with 10mL of the Millipore  Chemilucent 
Plus Western Blot Enhancing Kit (Product number: 2650) in a small plastic container 
before being imaged on a Bio-Rad ChemiDoc system and Image Lab software (Bio-Rad). 
 
Factor Xa Digests 
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0.01, 0.1, or 1 ng/µL of Factor Xa (NEB; product number: P8010S) was incubated with 1 
µg of GST-DNA binding domain either immobilized on glutathione sepharose beads or 
in solution. For the digestions performed on the bead support, GST-DNA binding domain 
was first incubated with glutathione sepharose beads for 30 minutes at room temperature. 
The beads with the immobilized protein were then transferred by pipette to a solution 
containing 10 µL of 20 mM Tris-HCl pH 8.0 with 100 mM NaCl and 2 mM CaCl2. For 
the digestion performed in solution, GST-DNA binding domain was first eluted from 
glutathione sepharose beads with 10 µL of 50 mM Tris-HCl pH 8.0 with reduced 
glutathione. Factor Xa digest was performed at 4 or 37˚C for 2 or 16 hours. The reaction 
conditions used for all experiments besides the Factor Xa pilot experiment are 1 ng/µL of 
Factor Xa incubated for 2 hours at 37˚C. 
 
Endoproteinase AspN Digests 
For native digestions, 1 µg/µL of Endoproteinase AspN (NEB; product number: P8104S) 
was incubated with 1 µg of LSF DNA binding domain for 16 hours at 37˚C in a 10 µL 
solution containing 50 mM Tris-HCl pH 8.0 with 2.5 mM ZnSO4. For denatured 
digestions, the DNA binding domain was first denatured in a solution containing 6 M 
guanidinium-HCl and incubated for 5 minutes. Prior to digestion, this sample was then 
diluted to 2 M guanidinium-HCl with 50 mM Tris-HCl pH 8.0 with 2.5 mM ZnSO4. The 
reaction was performed in a 10 µL reaction with 1 µg/µL Endoproteinase AspN for 16 
hours at 37˚C. The denatured method was used for all LC ESI-MS experiments. 
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Peptide Purification on Reverse Phase C-18 Spin Columns 
Pierce Biotechnology C-18 spin columns were used to prepare the peptide samples for 
the LC ESI-MS experiments. In order to prepare the peptide samples for binding to the C-
18 resin, 10 µL of Endoproteinase AspN digest was mixed by pipette with 3.33 µL of 2% 
trifluoroacetic acid (TFA) in 20% acetonitrile (ACN). The column was activated with 
200 µL 70% methanol and centrifuged at 1,500xg for 1 minute. The flow-through was 
removed and the activation step was repeated two additional times. 200 µL of 0.5% TFA 
in 5% ACN was used to equilibrate the column. The column was centrifuged at 1,500xg 
for 1 minute and the flow-through was removed. The equilibration step was repeated one 
additional time. All 13.33 µL of the activated sample was placed on top of the resin bed 
with a pipette. The column was placed into a new microcentrifuge tube and centrifuged at 
1,500xg for one minute. The flow-through was taken by pipette and reapplied to the top 
of the resin bed to maximize absorption of the peptide sample. The column was 
centrifuged at 1,500xg for one minute and the flow-through was removed. The column 
was then washed with 200 µL of 0.5% TFA in 5% ACN and centrifuged at 1,500xg for 
one minute. The wash step was repeated three additional times. The column was placed 
into a new microcentrifuge tube and 25 µL of 50% ACN was added to elute the bound 
peptides. The column was centrifuged at 1,500xg and the flow-through was collected and 
transferred to a clean tube. The elution step was performed again in order to ensure all 
bound peptides were collected. The final sample volume was 50 µL. 
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LC ESI-MS Experiment 
All LC ESI-MS experiments were performed by the Chemical Instrumentation Center of 
Boston University under the direction of Dr. Norman Lee. A 50 µL sample of 10 µg of 
peptides in 50% ACN was submitted to Dr. Lee for the experiment. This sample was 
purified using Pierce Biotechnology C-18 spin columns as previously described. 
 
Biotinylation of p65 
All biotinylation experiments were performed according to the guidelines in the Pierce 
EZ-Link Sulfo-NHS-Biotinylation Kit (product number: 21425). Biotinylation reagent 
was added at a 20 fold molar excess and the reaction proceeded for 1 hour at 4˚C in 
1xPBS unless otherwise noted in the results section. Excess biotinylation reagent was 
removed with 2mL or 5mL Zebra Desalting Columns (Pierce) prior to sample use in 
downstream processes. For ELISA experiments where p65 (Trevor Siggers, Boston 
University) was bound to the LSF DNA binding domain during the biotinylation reaction, 
one molecule of DNA binding domain was added to one molecule of p65 in a high 
protein concentration 7 µL 1xPBS solution for 1 hour at 4˚C. The molecule to molecule 
ratio was calculated based on the molecular weight of the DNA binding domain and p65 
as well as the mass of the two proteins in solution. Because the p65 existed in an impure 
solution, the amount of DNA binding domain was moderately higher. Since Sulfo-NHS-
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Biotinylation is concentration dependent, when reactions had to be quenched prior to 1 
hour, 800 µL of 1xPBS was used (a 30:800 dilution) in order to dilute the biotinylation 
reagent. 
 
ELISAs 
All ELISAs were performed on Nunc MaxiSorp flat bottom 96-well plates (Affymetrix). 
The coating buffer was 100 µL 1xPBS per well. The 1xPBS recipe used was 2.7 mM 
KCl, 10 mM KH2PO4, and 138 mM NaCl at pH 7.2. In some experiments ELISA plates 
were prepared by coating with 1 pmol avidin (Pierce) per well while for others 100 pmol 
per well was used; identified in the Results section. The assay plate was coated with 
avidin for 48 hours at 4 ˚C. Unless otherwise noted, 100 µL of 10 ng/µL biotinylated p65 
was added to each experimental sample well. The biotinylated p65 was incubated for 16 
hours at 4 ˚C. Two blocking buffers were used in different experiments. Most 
experiments used 200 µL of 1% bovine serum albumin (BSA) (Sigma) in 1xPBS with 
0.05% Tween-20 (1xPBST) per well, with an incubation time of 16 hours at 4 ˚C. In 
some experiments, however, 300 µL per well Superblock (Pierce) was added to the plate 
and immediately removed - repeated two additional times. The wash buffer was 300 µL 
of 1xPBST per well. Three washes were performed following each incubation step for all 
ELISAs. All protein and antibody solutions were prepared in 1xPBS. GST-LSF DNA 
binding domain was added at 50 µL per well for 1 hour at room temperature. All 
antibodies were added at 100 µL per well and incubated for 30 minutes at room 
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temperature. All antibody dilutions are described in the results section. The detection 
substrate used was 50 µL 3,3’,5,5’-Tetramethylbenzidine (TMB) (Pierce). The 
development reaction was quenched with 50 µL 0.2 M H2SO4. The signal was read at an 
absorbance of 450 nm by a Spectra Max M5 plate reader. 
 
Results 
 
Development of a set of protein domain constructs that collectively span the LSF 
Sequence 
 
 To elucidate the region of interaction between LSF and candidate binding 
proteins, it was necessary to divide the LSF sequence into separate regions for study. This 
was important because it allowed me to identify the domains within LSF that participate 
in a given protein-protein interaction, and eliminate non-interacting domains from future 
studies. I utilized a panel of seven LSF fragment constructs, two of which I generated and 
the remaining five which were a kind gift of Gene Chin. These constructs collectively 
spanned the entire LSF sequence, with individual constructs encoding the DNA binding 
domain, SAM domain, and ubiquitin-like domain, as well as the N-terminal region to half 
of the DNA binding domain, the linker regions between the DNA binding domain and 
SAM domain, and the C-terminal region (Figure 1a). A full-length LSF construct was 
also designed to function as a control in subsequent experiments. All constructs were 
tagged with a 26 kDa glutathione S-transferase (GST) protein tag for affinity purification 
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and enhanced stability in solution. The GST protein was encoded using a pGEX-5x-1 
vector (GE Healthcare) which places the GST protein N-terminal to the fusion protein, 
connected by a 4 amino acid linker containing a cleavage site for the sequence specific 
protease, factor Xa.  
GST-LSF DNA constructs were generated using sequence information from the 
NCBI database (Shirra et al. 1994) as well as domain sequence predictions from 
Kokoszynska et al (Kokoszynska et al, 2008). The GST-LSF constructs from pGEX1-4, 
kindly provided by Gene Chin, cover the full LSF sequence. The proteins expressed by 
the four truncated GST-LSF constructs pGEX1-4 overlap by 11 to 37 amino acids with 
their adjacent constructs. Not including the GST tag, the proteins expressed by the 
pGEX1, pGEX2, pGEX3, and pGEX4 constructs are 180, 151, 115, and 120 amino acids 
respectively (Figure 1a). Furthermore, the LSF DNA binding domain encoded by the 
DBD construct is 195 amino acids while the SAM domain encoded by the SAM construct 
is 63 amino acids (Figure 1a). Because the pGEX4 construct contains the full sequence of 
the ubiquitin-like domain of LSF, a separate ubiquitin-like domain construct was not 
generated. Sequence identity and orientation of all DNA constructs was confirmed using 
restriction enzyme digestion as well as by sequencing. 
 
GST LSF constructs successfully express GST fusion proteins 
 
 The seven individual DNA constructs described above were expressed in bacteria 
for use in future binding studies. The main criteria for acceptable protein constructs were 
18 
 
that the protein should be soluble, have the correct size by SDS-PAGE, and be of high 
purity. To this end, I utilized BL21 T7 Express lysY/Iq competent Escherichia coli (E. 
coli) as an expression host. The benefits of this system are the absence of bacterial 
proteases Lon and OmpT, tight control of expression by lacIq, use of T7 RNA 
polymerase for expression, and resistance to accidental lysis during expression due to 
lysY. By utilizing the bacterial lac operon for expression and the repressor lacIq, toxic 
mammalian proteins can be expressed, and T7 RNA polymerase ensures leaky expression 
is minimized. Basal expression of T7 RNA polymerase is further controlled by lysY 
which encodes an amidase deficient T7 lysozyme that binds the T7 RNA polymerase in a 
1:1 protein-protein complex (Zhang and Studier, 1997). T7 RNA polymerase-lysozyme 
complex formation is inhibited by an increased rate of T7 RNA polymerase elongation 
complex formation as T7 lysozyme lacks the ability to bind the elongation complex 
(Zhang and Studier, 1997). This allows full length mRNA transcripts to be produced 
following induction of the lac operon by IPTG. In addition, accidental lysis does not 
occur upon induction. Furthermore, the absence of bacterial proteases OmpT and Lon 
ensures that the expressed protein is less likely to be degraded after translation. Protein 
purity, and the size of each expressed construct, was determined by SDS-PAGE. 
The predicted sizes of the DNA binding domain, SAM domain, and the expressed 
proteins from the pGEX1-4 constructs without the GST fusion partner are 21.3, 6.8, 19.8, 
16.5, 12.5, and 13.2 kDa, respectively (Figure 3b). The GST fusion partner contributes an 
additional 26 kDa to each construct. SDS-PAGE analysis confirmed the sizes of the 
expected protein species (Figure 4). The pGEX1 expressed protein migrates slightly 
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faster than the expected size of 46 kDa in comparison to the expressed protein from 
pGEX2 (expected mw = 43kDa). The pGEX4 expressed protein also migrates slightly 
faster than the expected size of 39.2 kDa in comparison to the expressed protein from 
pGEX3 (expected mw = 38.5 kDa). These results were observed multiple times. The 
pGEX1-4 constructs were provided by Gene Chin and her SDS-PAGE analysis confirms 
that they run at their expected sizes. Her analysis of the pGEX1-4 DNA constructs by 
sequencing and restriction enzyme digestion also shows that the DNA constructs are the 
correct size. This means that an error most likely occurred in transfer to the BL21 host, 
protein expression, or in the preparation of the polyacrylamide gel. Since the pGEX1-4 
DNA sequences were confirmed by sequencing and restriction enzyme digest post-
transformation, the problem is most likely in protein expression or in preparation of the 
polyacrylamide gel. Because the sizes of the pGEX1-4 DNA constructs were confirmed 
to be accurate, I concluded that the inconsistencies in the migration of the expressed 
proteins were acceptable and the proteins were deemed appropriate for further study.  
 
YY1 and p65 from mammalian cell extracts bind LSF’s ubiquitin-like domain  
 
 Previous work from Coull et al. and Bing et al. shows that LSF binds both YY1 
and p65, respectively. I therefore decided to use YY1 and p65 as the principle candidate 
proteins to identify protein-protein interaction sites on LSF. Interestingly, while Coull et 
al. showed that YY1 binds to LSF at the DNA binding domain, p65 was only shown to 
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bind with full-length LSF (Bing et al, 2000). Therefore, I was interested in determining 
the region on LSF where p65 binds. 
To test for p65 and YY1 binding to LSF, I captured the expressed GST-LSF 
proteins to glutathione sepharose beads before incubating the beads with U2OS 
mammalian cell extracts containing p65 and YY1. The beads were then washed three 
times to remove any non-specific binding proteins. The bound proteins were eluted with 
reduced glutathione and analyzed by SDS-PAGE followed by western blot. The 
membrane was immunoblotted with anti-p65 or anti-YY1 polyclonal antibodies, as 
described in Methods. The results showed that YY1 binds to the LSF fragment encoded 
by the pGEX4 construct, corresponding to amino acids 383 - 502 of the LSF sequence, as 
well as to full length LSF as expected. Binding of YY1 to the LSF fragments encoded by 
the pGEX1 construct (amino acids 1 – 180) and the pGEX2 construct (amino acids 169 – 
319) was also observed, although the bands corresponding to these binding interactions 
appeared to be much fainter than those observed for the pGEX4 construct suggesting that 
they were due to non-specific binding of the antibody (Figure 5). The faint band for full-
length LSF is most likely due to poor expression of this construct since larger culture 
volumes were needed to express suitable amounts of protein for the experiments. When 
assaying for p65 similar results were observed, with a more intense band being displayed 
for pGEX4 and fainter bands for pGEX1 and pGEX2 (Figure 6). All protein binding 
experiments were performed in triplicate, however, the binding of YY1 and p65 to LSF 
was not investigated with cell extracts from different cell lines. The doublet band 
indicated in Figures 6 and 8 was determined to be due to a bacterial protease non-
21 
 
specifically captured on the glutathione bead resin during incubation of the glutathione 
sepharose beads with the bacterially expressed GST-LSF proteins (Figure 9). As seen in 
Figure 9, the doublet band is not present in the input lane but when incubated with 
glutathione sepharose beads that were treated with lysed BL21 cells, the doublet becomes 
noticeable. This finding may indicate that a bacterial protease from the BL21 cells is non-
specifically binding to the glutathione beads and is cleaving p65 into a cleavage product 
that is indicated by the smaller doublet band. This is significant because it presents a 
plausible argument that both the band for p65 and the doublet are representative of p65. 
Since the pGEX4 construct encodes a protein fragment containing the ubiquitin-like 
domain, these results of these binding experiments suggest that both p65 and YY1 bind to 
the ubiquitin-like domain of LSF. 
 
Addition of phosphatase inhibitors shifts p65 and YY1 binding to the DNA binding 
domain of LSF 
 
 Because Coull et al. showed that YY1 binds to the DNA binding domain of LSF, 
while my data showed binding to the ubiquitin-like domain of LSF, it became necessary 
to determine the cause of the discrepancy. I hypothesized that perhaps the 
phosphorylation state of the p65 and the YY1 was different in our experiments compared 
to the earlier work of Coull et al., and that this difference might account for the different 
binding properties we observed for these proteins with LSF. Post-translational 
modifications have been shown to affect protein-protein binding in protein interaction 
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domains (Pawson and Nash, 2003). We therefore repeated the binding experiments but 
included phosphatase inhibitors in the preparation of the U2OS cell extracts to maintain 
the phosphorylation state of the p65, YY1, and other proteins in these extracts. The 
U2OS cell extract samples were treated prior to binding GST-LSF with a phosphatase 
inhibitor cocktail containing  
cantharidin, (-)-p-bromotetramisole oxalate, and calyculin A, responsible for inhibiting a 
range of threonine/serine and alkaline phosphatases. When I repeated the binding assays 
with the seven GST-LSF constructs, under these new conditions YY1 appeared to bind 
the DNA binding domain, full length LSF, and the pGEX1 expressed protein (Figure 7). 
These results differed dramatically from what was observed without inclusion of 
phosphatase inhibitors in the extract samples. Blotting with an anti-p65 antibody mirrored 
the results seen for YY1, showing binding with the DNA binding domain, full length 
LSF, and pGEX1 expressed proteins (Figure 8). As described above, the pGEX1 
construct contains the N-terminal region of LSF along with the majority of the DNA 
binding domain (Figure 1b). The pGEX2 construct contains a fraction of the DNA 
binding domain corresponding to amino acids 104 – 259 of the LSF sequence (Figure 
1a). Since binding of YY1 and p65 was observed for both the pGEX1 and DNA binding 
domain constructs (residues 65 to 259 of the LSF sequence) but not the pGEX2 construct, 
binding most likely involves regions of the LSF sequence located between residues 65 
and 103 (Figure 1b). This 38 amino acid sequence, residues 1 – 38 of the DNA binding 
domain, corresponds to about one fifth of the full DNA binding domain sequence. My 
results therefore narrow the region of investigation for future experiments to residues 65 
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– 103 of the LSF sequence. The fact that binding of p65 and YY1 shifts when 
phosphatase inhibitors are present suggests that binding may involve a more elaborate 
mechanism than expected depending on the phosphorylation or dephosphorylation of one 
of more of the participating proteins. 
 
Peptide Identification Assay Design and Optimization of Factor Xa Cleavage 
 
Since an aim of the study was to determine the specific LSF peptide sequence or 
sequences responsible for binding p65 and YY1, I developed a new assay to investigate 
this question. The assay involves cleaving the DNA binding domain of LSF into peptide 
fragments with a site-specific protease, and then capturing these fragments on beads to 
which p65 had been immobilized. For the binding peptides to be identified, the bound 
p65 would have to be denatured thereby releasing the bound peptides for analysis. This 
release can be problematic for protein tags like GST because the conditions necessary for 
the denaturation of p65 would also denature the GST resulting in undesired elution from 
glutathione column. I therefore decided to use biotinylation and the streptavidin-biotin 
interaction for coupling of the p65 to the beads, since the high affinity of biotin for 
streptavidin (Kd = 10-15 M) would likely withstand low to medium concentrations of 
denaturants allowing elution of the LSF peptide without washing off the p65. 
Identification of binding peptides would be performed by electrospray ionization mass 
spectroscopy (ESI-MS). For the ESI-MS identification, the eluted peptide sample would 
be compared to two control samples. The first control sample would consist of the flow-
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through from the streptavidin-biotinylated p65 beads after the addition of protease 
digested DNA binding domain peptide fragments. The second would consist of a protease 
digestion of the DNA binding domain. The second control sample would not be applied 
to the beads and would contain all the peptide fragments capable of binding the 
biotinylated p65. Both control samples along with the sample eluted from the 
streptavidin-biotinylated p65 beads would be analyzed by LC ESI-MS. The mass-to-
charge ratio of the samples would then be compared to the site-specific protease peptide 
fragment map for the DNA binding domain as well as the DNA binding domain amino 
acid sequence to identify the sequences of the binding peptides. This is necessary because 
the mass-to-charge ratio can increase or decrease depending on how the sample is ionized 
and a single peptide species can therefore resemble different peaks in the ESI-MS results. 
By comparing the peptides eluted from the streptavidin-biotinylated p65 beads to the two 
control samples, a consensus can be formed on the binding peptides mass from the mass-
to-charge ratio. Furthermore, ESI-MS is not a direct sequencing method and sequence 
identity can only be determined by comparing the mass of the peptide from the mass-to-
charge ratio to the predicted size of the peptide fragment map. 
Because my LSF DNA binding domain construct contains a GST tag that is 
susceptible to cleavage by proteases and chemical agents, the first step in designing the 
peptide identification assay was to show that the GST tag could be removed on the GST-
DNA binding domain fusion protein. The pGEX-5x-1 vector contains a sequence coding 
for the recognition site for the protease Factor Xa proximal to the 5’ end of the vector’s 
cloning site. This places the Factor Xa recognition site in the linker region between the 
25 
 
GST tag and the fusion partner allowing the GST tag to be cleaved using Factor Xa. To 
determine the optimal cleavage conditions, I tested nine different reactions using the 
DNA binding domain, and analyzed the results by Coomassie Brilliant Blue staining on a 
polyacrylamide denaturing gel (Figure 10). The amount of Factor Xa, the temperature of 
the reaction, the length of the reaction, and whether the reaction was performed with the 
GST-DNA binding domain bound to the glutathione sepharose beads or in solution were 
the conditions that were altered. Based on this experiment, for future Factor Xa reactions 
I chose conditions of 1 ng/µL of Factor Xa incubated at 37°C for two hours with the 
GST-DNA binding domain fusion protein bound to the glutathione sepharose beads, 
because these conditions resulted a faint band at  about 47 kDa and a bright band at about 
13 kDa. The expected molecular weight of the GST protein is 26 kDa and the linker 
region between GST tag and fusion protein is 440 daltons. The DNA binding domain is 
calculated to be 21.5 kDa based on the LSF sequence and domain predictions by 
Kokoszynska et al however the band for the protein appears around 13 kDa on the 
polyacrylamide gel. When sequenced, the DNA insert for the GST-DBD construct was 
found to match the predicted DNA binding domain DNA sequence at 100% similarity 
(BLAST: bl2seq). Therefore, it is most likely that the 13 kDa band is the DNA binding 
domain and it is running at a lower molecular weight most likely due to the same issues 
affecting the expressed proteins from the pGEX1, pGEX2, pGEX3, and pGEX4 
constructs as mentioned in the last paragraph of the “GST LSF constructs successfully 
express GST fusion proteins” section of the results. Furthermore, a Factor Xa cleavage 
site is not present in the DNA binding domain sequence. This suggests that additional 
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proteolysis of the DNA binding domain is unlikely and that the 13 kDa band is not 
representative of the DNA binding domain being cleaved multiple times. 
 
Endoproteinase AspN Cleaves Denatured LSF DNA Binding Domain 
 
 Cleaving the DNA binding domain into peptides fragments is important for the 
identification of the protein-protein binding site on LSF. This is because it is easier to 
determine the identity of individual peptide fragments than it is to uncover the region of 
binding on a full length protein without a crystal structure. Digestion of protein into 
peptide fragments can be performed using proteases or chemical agents. I decided to use 
proteases because they are believed to be more reliable and safer than chemicals. To that 
end, I utilized ExPASy’s peptide cutter tool (Hoogland et al. 2005) to predict where a 
select set of proteases would cleave the DNA binding domain of LSF. My criteria for 
selecting a protease for the cleavage experiments was that multiple peptide fragments 
would be generated, and that these fragments would be on average greater than six amino 
acids but less than one-hundred and twenty. These rules were selected because the 
binding motif would most likely be six amino acids or greater, while a one-hundred and 
twenty amino acid fragment would encompass half of the DNA binding domain and 
therefore provide only limited information on the location of the binding site. However, 
smaller peptide fragments were more disfavored because large peptides can be further 
digested into smaller fragments with subsequent proteases and the assay could be 
repeated again to localize the specific binding site. Using ExPASy’s peptide cutter tool, I 
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found that the protease Endoproteinase AspN cleaved the DNA binding domain eleven 
times, giving fragments with an average size of 21 amino acids (Figure 11). 
 Endoproteinase AspN was used to cleave LSF DNA binding domain expressed 
from the GST-DBD construct, after removal of the GST tag using the previously 
described optimized conditions. 1 µg of protein was digested by 1 µg of Endoproteinase 
AspN in 50 mM Tris-HCl, 2.5 mM ZnSO4 pH 8.0 for 16 hours at 37°C. The sample was 
then mixed with SDS-sample buffer and analyzed on a 20% SDS-PAGE gel with 
Coomassie Brilliant Blue staining alongside a control lane containing uncleaved DNA 
binding domain. After destaining, both the control band and the sample band were 
present at about 25 kDa suggesting that Endopretinase AspN digestion was unsuccessful. 
Since protein folding can inhibit protease digest and since native protein is not a 
requirement for downstream aspects of the assay, I denatured 1 µg of DNA binding 
domain in 6 M guanidine-HCl (Apffel et al, 1995). The sample was then diluted to 2 M 
guanidium-HCl prior to digestion with Endoproteinase AspN (Apffel et al, 1995). 
Lysozyme (molecular weight = 14.3 kDa) was used as a control substrate, and 70% 
formic acid as a control cleavage agent, because lysozyme can be digested by 
Endoproteinase AspN and formic acid fragments the DNA binding domain at the same 
sites as Endoproteinase AspN since it cleaves at the N-terminal bond of aspartic acid 
residues. The denatured samples were also compared against native samples digested as 
previously stated. All samples were analyzed on a 10-20% pre-made SDS-PAGE gradient 
gel (Thermo Fisher) with Coomassie Brilliant Blue staining (Figure 12). Both lysozyme 
and DNA binding domain samples were cleaved by Endoproteinase AspN as indicated by 
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the absence of a band around 25 kDa for the DNA binding domain and 14 kDa for 
lysozyme and the presence of a band at 25 kDa for the DNA binding domain and 14 kDa 
for lysozyme. Formic acid also cleaved native lysozyme and DNA binding domain 
samples. These results suggest that LSF DNA binding domain needs to be denatured 
prior to digestion by Endoproteinase AspN and that formic acid can also digest the DNA 
binding domain. However, it should be noted that if formic acid is used, the acid will 
need to be neutralized as it will most likely interfere with downstream assay processes. 
These results also suggest that the inconsistencies associated with the migration of the 
pGEX1-4 expressed proteins and the GST cleaved DNA binding domain in 
polyacrylamide gels is an issue involving the preparation of the polyacrylamide gels. This 
is because the DNA binding domain sample in Figure 12 is similar to the sample in 
Figure 10 with the exception that the sample in Figure 12 was electrophoresed on a pre-
cast gradient polyacrylamide gel and the sample in Figure 10 was electrophoresed on a 
15% polyacrylamide gel made in the lab. The DNA binding domain sample in Figure 12 
migrates closer to its expected molecular weight of 21.5 kDa at 25 kDa while the DNA 
binding domain sample in Figure 10 migrates at 13 kDa.    
 
ESI-MS Can Detect LSF DNA Binding Domain Peptide Fragments 
 
 Since peptide fragments of the DNA binding domain could be generated by 
Endoproteinase AspN digestion using the denaturing protocol, it became possible to 
validate downstream identification methods. Validation is important to determine if the 
29 
 
assay can produce the intended data. I decided to use HPLC-coupled ESI-MS for as the 
detection method (LC ESI-MS). For this method, samples are first concentrated on an 
HPLC column before being analyzed by ESI-MS. All LC ESI-MS studies were 
performed by Senior Instrument Specialist Dr. Norman Lee from the Chemical 
Instrumentation Center at Boston University. 
 10 µg of LSF DNA binding domain was denatured and digested by 
Endoproteinase AspN as previously described. I then captured the fragmented peptides 
on a C-18 spin column. This method is advantageous because it removes the guanidium-
HCl as well as the Endoproteinase AspN as the C-18 resin is suitable for binding small 
peptides but not larger proteins. The peptides were eluted in 50 µL of 1:1 
acetonitrile/water solution and given to Dr. Norman Lee for processing. The resulting 
chromatogram from the coupled HPLC column (Figure 13), along with the mass-to-
charge readouts from the ESI-MS, were analyzed and the peptide fragments were 
assigned to the individual chromatogram peaks (Table 1). All peptide fragments except 
the 3,960 dalton fragment were assigned to peaks on the chromatogram. However, the 
3,960 dalton fragment may have been too large to be captured by the MS detector. The 
chromatogram shows a peak at 1.45 minutes which was not assigned a peptide fragment, 
and so it is possible that the 3,960 dalton fragment corresponds to this peak. Regardless, 
these data suggest that the DNA binding domain peptide fragments generated by 
Endoproteinase AspN digestion can be detected by LC-MS and thus that this method of 
detection can be used for future studies. 
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Biotinylated p65 binds LSF’s DNA Binding Domain 
 
 An important aspect of the binding peptide identification assay is the capture of 
natively structured, active p65 to the beads. Native p65 is needed because the protein will 
not bind peptide fragments if it is denatured. Furthermore, the active p65 must be placed 
on a bead support so it can be manipulated and carried through multiple assay steps. To 
this end, I decided to biotinylate of p65 and use streptavidin capture as a method to bind 
active p65 to a bead support. However, there are multiple biotinylation chemistries with 
different conditions to consider. I chose to use primary amine directed biotinylation 
through Pierce Biotechnology’s Sulfo-NHS-Biotinylation Kit. This reagent specifically 
labels lysine residues and the N-terminal amine of proteins. However, because lysines 
may be involved in the protein-protein interaction site of p65, there is a possibility that 
biotinylation might render the protein inactive either through blocking the binding site or 
by inducing conformational changes in the protein that occlude the binding pocket. To 
test this possibility I used the GST-LSF bead binding assay to test the ability of the 
biotinylated p65 to bind to GST-DNA binding domain captured on glutathione sepharose 
beads. Recombinant p65 protein expressed in E.coli was generously provided by Dr. 
Trevor Siggers of Boston University.  
 The purity of the provided protein was assessed by 10% SDS-PAGE analysis with 
Coomassie Brilliant Blue staining (Figure 14). The result showed that protein sample was 
only partially purified with three major bands and multiple minor bands contaminating 
the sample. Because the contaminating proteins were expressed in bacteria, I did not 
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think they would interfere with downstream aspects of the assay since it is not likely that 
proteins expressed from a non-pathogenic bacterial strain (BL21 E. coli) would interact 
or inhibit a mammalian transcription factor. I therefore decided to use the protein 
preparation anyway. However, the use of this protein preparation could be problematic 
because the Coomassie Brilliant Blue staining does not give any indication of protein 
activity and so the ratio of active p65 to inactive p65 cannot be determined from the stain. 
Furthermore, because the concentration of p65 is lower than the concentration of the 
protein preparation, more total protein will have to be used for the assay. Biotinylation 
was performed according to the procedure recommended in the instructions for the Pierce 
Kit which recommends using a 20 fold molar excess of biotinylation reagent. The 
biotinylation reagent is unstable under the conditions used for labeling, and after 60 
minutes at 4 °C the reactivity of the reagent decreases. Excess biotin was removed 
through the use of a provided Zebra Desalting Column. 100 ng of the biotinylated p65 
was incubated with GST-DNA binding domain on glutathione sepharose beads for 16 
hours at 4° C, before being eluting with reduced glutathione. The same procedure was 
performed with non-biotinylated p65 as a control. The two assay samples, along with 100 
ng of non-biotinylated and biotinylated p65, were analyzed on a denaturing 10% 
polyacrylamide gel and then transferred to a PVDF membrane. The membrane was first 
incubated with an anti-p65 antibody before being stripped and then re-incubated with a 
streptavidin-HRP conjugate (EMD Millipore; product number: 18-152). The anti-p65 
immunoblot shows the binding of p65 to GST-DNA binding domain (Figure 15a). When 
incubated with the streptavidin-HRP conjugate, binding of biotinylated-p65 to GST-DNA 
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binding domain is observed (Figure 15b). However, when the band corresponding to the 
biotinylated p65 bound to the DNA binding domain is compared to the input sample, the 
band is observed to be fainter for the bound biotinylated p65. This result suggests that 
only a fraction of the biotinylated p65 is active. Furthermore, this data also suggests that 
the DNA binding domain of LSF can bind recombinant p65. 
 
ELISA Development to Quantify the Amount of Active Biotinylated p65 
 
 In order for the peptide binding assay to function as intended, a large percentage 
of the biotinylated p65 must be active. This issue is compounded by the fact that the 
donated p65 is not pure because in order to calculate the optimal amount of biotinylation 
reagent to use in the reaction, the exact concentration of p65 must be known. This cannot 
be determined easily from a partially purified sample. This presents a problem because 
excessive biotinylated can render the protein inactive, while insufficient biotinylation will 
not generate enough biotinylated p65 for use. Because it is difficult to determine how 
much of the p65 sample is biotinylated in the western blot, I began developing an ELISA 
to quantify the amount of biotinylated active p65. 
 The ELISA plate was coated for 48 hours at 4°C with 1 pmol of avidin per well in 
a 1xPBS coating buffer, to generate a surface that could capture biotinylated p65. This 
coating allows only biotinylated protein to be captured, while non-labeled p65 is washed 
off, ensuring that the signal produced from the assay is due solely to binding of 
biotinylated p65 and does not include any significant contribution from unlabeled p65. 
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The plate was washed three times with 1xPBST before blocking with 1% BSA in 
1xPBST for 16 hours at 4 °C. The plate was washed three times and then incubated with 
10 ng/µL of biotinylated p65 for 16 hours at 4°C. p65 was biotinylated according to the 
same conditions used for the previously described western blot. The plate was washed 
three times and then incubated with 50 µL of 10 nM or 100 nM GST-DNA binding 
domain for 1 hour at room temperature. GST-DNA binding domain was used because no 
antibody currently exists for the DNA binding domain of LSF. The GST-DNA binding 
domain solves this problem, however, because the DNA binding domain can bind p65 
while the GST tag can be detected by a GST antibody. Two different GST-DNA binding 
domain concentrations were used to probe for the ends of a dose response curve if the 
assay succeeded. The plate was washed three times and then incubated with 100 µL of 
0.4 ng/µL anti-GST antibody (Santa Cruz Biotech; product number: sc-459) for 30 
minutes at room temperature. The anti-GST antibody recognizes the GST-DNA binding 
domain bound to the biotinylated p65 immobilized on the avidin coated plate surface, and 
can be detected by an anti-rabbit IgG-HRP antibody. The secondary antibody used to 
detect the rabbit anti-GST antibody was the same used for the previously performed 
western blots. The plate was washed three times and incubated with a 1:4000 dilution of 
anti-rabbit IgG-HRP antibody for 30 minutes at room temperature. After incubation, the 
plate wash again washed three times and then incubated with 50 µL of 3,3’,5,5’-
Tetramethylbenzidine (TMB) for 15 minutes at room temperature. TMB is oxidized by 
horse radish peroxidase (HRP) and causes a color change that can be quenched and 
measured. The TMB reaction was quenched after 30 minutes with 50 µL of 0.2 M H2SO4 
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and the color change was measured at an optical density of 450 nm. A series of controls 
were included on the plate, each consisting of the reaction minus one assay component 
removed per control sample. When the experimental samples were compared to the 
controls, it was observed that the majority of the experimental sample signals were due to 
background from the GST-DNA Binding domain and the α-GST (Figure 16). This is 
because the signal for the 100 nM GST-DNA binding domain in the absence of p65 was 
equal to the 100 nM GST-DNA binding domain with p65, suggesting that the signal 
observed for the 100 mM GST-DNA binding domain experimental sample was really 
attributed to the non-specific binding of the GST-DNA binding domain and the anti-GST 
antibody. Furthermore, the anti-GST antibody contributes at least half of the background 
signal presented by the GST-DNA binding domain suggesting the background signal 
solely from the GST-DNA binding domain is not as high. This can be determined by the 
high signal for anti-GST antibody in the absence of the DNA binding domain. This 
means that part of the background signal attributed to the DNA binding domain is due to 
the non-specific binding of the anti-GST antibody. 
 For the next ELISA, I decided to test multiple biotinylation conditions as well as a 
range of anti-GST and anti-rabbit IgG-HRP antibody dilutions. This protocol allowed me 
to optimize the biotinylation reaction for different conditions using a single ELISA assay. 
The test biotinylation conditions were (i) a 40-fold M excess of biotinylation reagent, (ii) 
a 10-fold M excess of biotinylation reagent, and (iii) a 20-fold M excess of biotinylation 
reagent which was the same condition as used in the previous assay. A condition 
involving a ten minute reaction with a 20-fold M reagent concentration was also tested. 
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The assay procedure stayed the same as the last ELISA with the exception of a 1:15,000 
dilution for the anti-rabbit IgG-HRP antibody. There was no observable difference in the 
signal obtained among the biotinylation conditions though their overall signal was not 
high and did not exceed that of the GST-DNA binding domain control (Figure 17). Based 
on this experiment, 0.4 ng/mL of anti-GST antibody and a 1:15,000 dilution of anti-rabbit 
IgG-HRP antibody were selected as optimal concentrations, due to their low level of 
background signal (Figure 17). The 1:40,000 dilution of anti-rabbit IgG-HRP antibody 
resulted in a lower background signal than the 1:15,000 dilution but it was a concern that 
this dilution would produce little to no signal from the experimental samples if used for 
future ELISAs. 
 Since little to no signal was observed for the experimental samples when 
compared to the background signal, I decided to use multiple amounts of p65 per 
condition. This would produce a dose response curve, and the biotinylation condition that 
would lead to the more active p65 could be selected. The p65 amounts selected for each 
condition were 5 µg, 1 µg, and 0.2 µg. The assay procedure was the same as in the 
previous experiment except that 10 nM GST-DNA binding domain was used instead of 
100 nM. The control samples were designed to determine the background signal in the 
assay. They were (i) 10 nM GST-DNA binding domain with 0.4 ng/mL anti-GST 
antibody, and 1:15,000 anti-rabbit IgG-HRP, (ii) 0.4 ng/mL anti-GST antibody and 
1:15,000 anti-rabbit IgG-HRP, and (iii) 1:15,000 anti-rabbit IgG-HRP. The change in the 
amount of p65 added to the plate did not significantly affect the signal (Figure 18). 
However, the signal did exceed the 10nM GST-DNA binding domain background 
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control. Thus, 5 µg of p65 gave the same signal as 0.2 µg of p65 which does not make 
sense since an increase in bound p65 should allow for more GST-DNA binding domain 
to bind conferring a higher signal. One possible explanation for this result is that 1 pmol 
per well of avidin is not sufficient enough to capture more than 0.2 µg of p65 and 
therefore, each well would be representative of the result if only 0.2 µg p65 was captured 
even if 5 µg was added to the well. 1 pmol of avidin in a 100 µL solution is 10-8 M avidin 
and 0.2 µg of p65 is 3.08 x 10-8 M p65. Since one molecule of avidin can bind four 
molecules of streptavidin (Livnah et al. 1993), the amount of p65 1 pmol per well of 
avidin can optimally bind is 4 x 10-8 M. However, since a fraction of the avidin incubated 
on the surface of the plate will not be in a conformation to bind biotin, the amount of 
biotin 1 pmol per well of avidin can bind is slightly less than 4 x 10-8 M. If 5ug of p65 in 
a 100 µL solution is equal to 7.69 x 10-7 M and the avidin coating in the well can only 
bind slightly less than 4 x 10-8 M biotin, we would only expect around 4 x 10-8 M 
biotinylated p65 to be captured in the well; the remaining p65 would be washed away in 
the wash step. Therefore, the 1 pmol per well avidin coating can capture 0.2 µg of 
biotinylated p65 but a greater amount of protein will be reduced to about 0.2ug or higher. 
This means that any amount of biotinylated p65 greater than 0.2 µg will give the same 
signal as about 0.2 µg of protein. 
 In order to address the problem experienced in the previous ELISA experiment, I 
increased the amount of avidin per well to 100 pmol. This amount of avidin (10-6 M) 
should be able to bind at most 4 x 10-6 M biotinylated protein which is greater than the 
amount needed to bind 5 µg of p65 (7.69 x 10-7 M). Furthermore, in an attempt to 
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increase the amount of active biotinylated p65, I bound the LSF DNA binding domain 
without the GST tag to p65 prior to biotinylation. This would help increase the amount of 
active p65 because the presence of the DNA binding domain in the protein-protein 
interaction site on p65 would prevent any important amino acid residues involved in the 
binding of p65 to LSF from being biotinylated. However, this would likely cause both the 
DNA binding domain and p65 to become biotinylated but it was thought that the DNA 
binding domain would be stripped away from the p65 on binding to the avidin-coated 
plate since the affinity of biotin for avidin is high. This would then expose the amino acid 
residues protected by the DNA binding domain in the protein-protein interaction site on 
p65 so they could bind GST-DNA binding domain. It was also thought that the DNA 
binding domain would not contribute to the sample’s signal because it lacked the GST 
fusion protein detected by the GST antibody. Finally, I also utilized an anti-p65 antibody 
(Santa Cruz Biotech; product number: sc-372) raised to the C-terminal of p65. This 
antibody should detect the total amount of p65 present in the well and since non-
biotinylated p65 is washed away, it should detect only the amount of p65 that is 
biotinylated. This is important because by determining the amount of biotinylated p65 in 
the sample I can then determine how much biotinylated p65 is active by comparing the 
total amount of biotinylated p65 to the amount of biotinylated p65 that binds GST-DNA 
binding domain. In order to determine how much of the p65 antibody to use, I performed 
a dilution curve on an untreated plate coated with 1xPBST and blocked with 1% BSA in 
1xPBST. A 1:15,000 dilution of anti-rabbit IgG-HRP antibody was used to detect the 
amount of anti-p65 antibody nonspecifically bound to the assay plate. A buffer control 
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and an anti-rabbit IgG-HRP antibody control were also performed. A 1:3,000 dilution of 
anti-p65 antibdoy was chosen from the dilution curve because it was the lowest dilution 
that still showed a small degree of background signal (Figure 19). I felt this was 
important because I did not want to dilute the detection antibody too much and lose 
potential signal from future experimental samples. I then performed the previous ELISA 
again with three new samples containing the biotinylated p65, anti-p65 antibody, and 
anti-rabbit IgG-HRP antibody. Signal was observed for the experimental samples 
containing GST-DNA binding domain but the signal observed for the samples containing 
α-p65 did not exceed background (Figure 20). It was interpreted that the 1% BSA in 
1xPBST block was inefficient at preventing α-p65 from binding to the plate because the 
samples containing GST-DNA binding and detected by anti-GST antibody had 
significantly increased signal over the samples detected with anti-p65 antibody. This 
comparative increase in signal was not due to background signal as the GST-DNA 
binding domain control showed only a slight increase in signal over the buffer control. 
Furthermore, the samples detected by the anti-p65 antibody did not generate a significant 
amount of signal to exceed the background signal provided by the anti-p65 antibody 
control suggesting that the signal observed in the samples detected by the anti-p65 
antibody are due to background.  
 Since my previous block was shown to be ineffective, I performed a pilot 
experiment testing different blocking conditions. I tested the ability of 5% BSA in 
1xPBST, 5% sucrose in 1xPBST, 5% non-fat dried milk in 1xPBST, and Superblock 
(Pierce Biotechnology) to prevent non-specific binding of the anti-p65 antibody to the 
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plate’s surface. The candidate blocking conditions were also compared to the 1%BSA in 
1xPBST blocking condition for reference and to act as a control since 1%BSA in 
1xPBST was already shown to be ineffective at preventing non-specific binding of anti-
p65 antibody. I utilized 1:150, 1:300, 1:1,500, and 1:15,000 dilutions of anti-p65 
antibody. A buffer control was also included and the dilution of anti-rabbit IgG-HRP 
antibody used to detect the anti-p65 antibody was 1:15,000. The blocking conditions 
varied in their ability to prevent anti-p65 antibody from non-specifically binding the 
plate’s surface but Superblock performed the best since it had smaller overall background 
signal and tighter error bars (Figure 21). Now that I had optimized the blocking 
conditions for the p65 antibody, I performed the previous ELISA with 1:150 of anti-p65 
antibody and substituted Superblock for the 1% BSA in 1xPBST blocking condition. The 
biotinylation conditions of 20-fold M excess biotinylation reagent and 4-fold M excess 
biotinylation reagent resulted in a higher signal than 100-fold M excess biotinylation 
reagent the reagent (Figure 22). However, the control sample of anti-GST antibody with 
biotinylated p65 gave the same intensity in signal as the experimental samples. This 
would indicate that the anti-GST antibody is non-specifically binding the plate, except 
that the anti-GST antibody control shows minimal background signal. A potential 
explanation for this result is that some of the GST protein tag was removed from the 
glutathione sepharose beads during Factor Xa cleavage and contaminated the DNA 
binding domain preparation. During the biotinylation reaction, this GST protein would be 
biotinylated alongside the DNA binding domain and the p65 and would then stick to the 
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avidin-coated plate. Since the biotinylated GST would be captured on the avidin-coated 
plate, it would be easily detected by the α-GST leading to high background signal. 
 
Discussion 
YY1 and p65 Binding to LSF is Influenced by the Addition of Phosphatase 
Inhibitors 
 
 An interesting result of this thesis is that binding of both YY1 and p65 to regions 
on LSF shifts when phosphatase inhibitors are added during the preparation of U2OS cell 
extracts. Data has shown that in the presence of phosphatase inhibitors, binding occurs 
with LSF’s DNA binding domain (Figures 7 and 8). When phosphatase inhibitors are 
absent from the U2OS cell extract preperation, however, binding occurs with the 
ubiquitin-like domain of LSF (Figures 5 and 6). Furthermore, bacterially-expressed 
biotinylated p65 has been shown to bind LSF’s DNA binding domain in the absence of 
phosphatase inhibitors (Figure 15a). Since the GST-LSF constructs are expressed 
individually in bacteria and because binding is not seen at both the DNA binding and the 
ubiquitin-like domains in the absence of phosphatase inhibitors (in the event that the 
phosphate group was directing protein-protein interaction formation) the cause of the 
shift in binding is most likely occurring in the mammalian cell extract protein samples. 
This is further supported by the binding of biotinylated, bacterially expressed p65 to the 
DNA binding domain since these data were obtained in the absence of phosphatase 
inhibitors, whereas binding to the DNA binding domain required the presence of 
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phosphatase inhibitors for U2OS cell extract protein samples. However, it is unlikely that 
both YY1 and p65 are being phosphorylated at similar sites and that this phosphorylation 
is shifting the binding of both proteins to the same site on LSF because YY1 and p65 are 
different and unrelated transcription factors. This is further supported by the fact that 
phosphatase inhibitors weren’t used during the binding of biotinylated bacterially 
expressed p65 to the DNA binding domain since binding still occurred suggesting that 
another protein in the cell extract, other than YY1 or p65, is being phosphorylated. This 
phosphorylated protein would then be mediating the interaction between LSF and p65 
based on its phosphorylation state. The simplest explanation then is that the shift in 
binding from the ubiquitin-like domain to the DNA binding domain or vice versa is part 
of a more complex mechanism or pathway, as discussed below. 
 Scaffold proteins allow for the localization, compartmentalization, and 
organization of signaling cascades (Pan et al, 2012). By utilizing a complex network of 
protein-protein interactions, they are capable of ferrying signals from transmembrane 
receptors to targets in the nucleus through the association of multiple signaling kinases 
and interactions with other scaffold proteins (Pan et al, 2012). Some scaffolds can 
interact with transmembrane receptors as is the case with KSR, which is responsible for 
organizing the ERK pathway with the heterotrimeric G-protein gamma subunit, while 
other scaffolds can directly affect gene expression as is the case with scaffold JIP1 and 
JNK signaling (Pan et al, 2012). Furthermore, scaffold proteins can be regulated 
themselves through post-translational modification, the most common of which is 
phosphorylation and dephosphorylation (Pan et al, 2012).  
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 Docking proteins are similar to scaffold proteins in that they are responsible for 
localizing and organizing signaling molecules and they can also be regulated by post-
translational modification (Pan et al, 2012). However, they differ in that docking proteins 
tend to organize a small number of proteins at once and not large signaling cascades and 
they do not alter the properties of the proteins they bind (Pan et al, 2012). Insulin receptor 
signaling is mediated by phosphorylated docking proteins known as insulin receptor 
substrates (IRS) that are responsible for binding multiple insulin signaling kinases 
(White, 1998). IRS proteins contain phosphotyrosine binding and pleckstrin homology 
domains that are responsible for recognizing and binding the insulin receptor (White, 
1998) as well as multiple tyrosine residues that are phosphorylated and recognized by 
downstream signaling proteins containing SH2 and SH3 domains (Virkamaki et al, 
1999). Furthermore, multiple adaptor proteins, transforming proteins, structural proteins, 
and enzymes interact with IRS proteins but at unknown sites that are predicted to be 
outside the currently identified IRS protein-protein interaction domains (Virkamaki et al, 
1999). Adaptor proteins also bind multiple protein targets (Pan et al, 2012) and their 
association with docking proteins suggests that a range of higher order protein complexes 
may be possible through the interaction of adaptor and docking proteins and the proteins 
that bind them. 
 Since YY1 and p65 are expressed from different pathways and the exact signaling 
pathway(s) of LSF have not yet been elucidated, I hypothesize that YY1 and LSF as well 
as p65 and LSF are organized and localized by a docking protein. A scaffold protein 
could also be responsible, however, scaffold proteins handle large signaling cascades and 
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the simplest explanation is that only three proteins are binding together. It should be 
mentioned, however, that the data do not rule out the binding of LSF to YY1 or p65 as 
being part of a more intricate cascade in which case, a scaffold protein may be more 
appropriate. To continue the explanation, in its unmodified state the docking protein 
allows for the binding of the ubiquitin-like domain of LSF as well as either YY1 or p65. 
The compartmentalization of the two transcription factors in close proximity induces a 
protein-protein interaction between YY1 or p65 and the DNA binding domain of LSF. 
The formation of this protein-protein interaction is viable in solution but would occur at a 
faster rate on the docking protein due to its localization function. Interactions between 
LSF or p65/YY1 in solution to its binding partner on the docking protein would not occur 
due to steric hindrance from the docking protein. When phosphorylated, the docking 
protein would undergo a conformational change thus releasing LSF bound to either p65 
or YY1. When dephosphorylated by a phosphatase, the docking protein would return to 
its unmodified state and be able to bind substrates again. The LSF-p65 or LSF-YY1 
complex could then translocate to the nucleus and interact with promoter targets. Such a 
mechanism might be advantageous for LSF as a nuclear localization sequence has not yet 
been found for the protein. YY1 contains a nuclear localization sequence in its C-terminal 
region (McNeil et al, 1998) while p65 contains a nuclear localization sequence in its Rel 
homology domain (Perkins et al, 2007). It may be that LSF translocates into the nucleus 
by binding to a protein that already has the ability to do so. An alternate but related 
hypothesis is that LSF and p65 or YY1 may be bound by a regulatory complex similar to 
IκB in the NFκB pathway. However, the IκB complex binds related Rel proteins whereas 
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p65, YY1, and LSF are all unrelated, making this hypothesis unlikely. A third hypothesis 
is that dissociation of p65 and LSF from the docking protein does not occur. In this 
hypothesis, the docking protein is capable of binding both the ubiquitin-like domain and 
the DNA binding domain of LSF depending on its phosphorylation state. This hypothesis 
is inherently simpler than the first described hypothesis however if this is the case, the 
protein would be carried along with p65/YY1 and LSF during transcriptional regulation 
unless it dissociates at a later point due to other interactions or post-translational 
modifications. 
 One way to determine the identity of the potential docking protein is to use the 
GST-LSF bead binding assay with HPLC tandem mass spectroscopy (LC-MS/MS). In 
this assay, GST-LSF is bound to glutathione sepharose beads and then incubated with 
recombinant p65. The beads are washed to remove non-specific binding proteins and then 
incubated with U2OS cell extracts. Since LSF is bound to p65, the only proteins that will 
bind the LSF-p65 complex are proteins that can bind to both LSF and p65 as well as 
proteins that can bind to the sites on LSF and p65 that are not occluded from the 
complex’s formation. The beads are washed again to remove non-specific binding 
proteins and then the protein complexes are eluted with reduced glutathione. The eluted 
proteins are then prepared for mass spectroscopy and separated by HPLC (Chandramouli 
and Qian, 2009). After separation, the proteins are fractionated with trypsin and analyzed 
by MS/MS (Chandramouli and Qian, 2009). The individual fragments are compared to a 
MS trypsin fragment database for identification (Chandramouli and Qian, 2009). GST, 
LSF, and p65 can be removed from the analysis and the remaining proteins could either 
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be considered candidate docking proteins or be ruled out depending on their identity. The 
remaining proteins that weren’t removed could then be characterized further. 
 
 
Binding Peptide Identification Assay Design 
 
 The binding peptide identification assay consists of five parts designed to identify 
the region of the LSF DNA binding domain amino acid sequence responsible for binding 
p65. The individual stages are Factor Xa digestion of GST-DNA binding domain, 
Endoproteinase AspN digestion of DNA binding domain, biotinylation of p65, peptide 
capture by bound p65, and peptide detection with LC ESI-MS. At this time, only peptide 
capture by bound p65 remains to be tested while biotinylation of p65 needs to be further 
optimized. To summarize the results of this thesis in terms of the assay, Factor Xa 
cleaves GST from GST-DNA binding domain most efficiently when the reaction is 
performed at 37°C for two hours while the GST-DNA binding domain is bound to 
glutathione sepharose beads in the presence of 1 ng/µL of Factor Xa. Furthermore, 
Endoproteinase AspN can only digest denatured DNA binding domain. The peptide 
fragment detection method was also validated as it can detect all DNA binding domain 
peptide fragments with the exception of the 3,960 Dalton fragment though this fragment 
may appear on the HPLC chromatogram.  
 Future work should focus on optimizing the biotinylation of p65. Currently, three 
biotinylation reagent concentrations are being pursued; 4-fold molar excess, 20-fold 
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molar excess, and 100-fold molar excess of biotinylation reagent. In Figure 22, the 
amount of biotinylated p65 captured and detected with anti-p65 antibody is greater for 4-
fold molar excess and 20-fold molar excess samples than the 100-fold molar excess 
sample. However, the signals overall are low and do not reflect the signal expected for 1 
µg of protein. Two possible explanations exist for this result. The first is that the amount 
of p65 in the sample is dramatically lower than expected and the current signal is the best 
1 µg of this protein preparation can perform. The second is that because the biotinylation 
reagent is highly reactive, even in solid form, the biotinylation reagent could have 
exceeded its shelf life and have lost reactivity as a result. A solution for both explanations 
is the acquisition of fresh biotinylation reagent coupled with the purchase or expression 
of a mostly pure p65 protein preparation.  
 The ELISA in its current form is already ready for biotinylation optimization. The 
amount of avidin per well, concentration of GST-DNA binding domain, amount of α-
GST, dilution of α-rabbit IgG-HRP, and the dilution of α-p65 at 100 pmol per well, 
10nM, 0.4 ng/mL, 1:15,000, and 1:150 respectively has been found to be sufficient. With 
pure p65 biotinylated with new reagent, it is probable that the p65 biotinylation reaction 
can be optimized with the existing assay.  
Once optimized, the biotinylated p65 can be added to streptavidin agarose beads 
and the full binding peptide identification assay can be performed. Bead-bound p65 
would be incubated in a solution with LSF DNA binding domain peptide fragments 
produced from the Endoproteinase AspN digestion of the DNA binding domain. After 
binding, the streptavidin agarose beads would be centrifuged and the supernatant would 
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be purified with a C-18 spin column and analyzed by LC ESI-MS. The associated peaks 
in the HPLC chromatogram corresponding to the mass-to-charge ratios from the peptides 
analyzed by ESI-MS would represent the peptide fragments not bound to p65. Then, the 
streptavidin bound p65 would be denatured under moderate conditions so that p65 is 
denatured without the biotin-streptavidin interaction being affected. Though improbable 
due to its high affinity for streptavidin, if some of the biotinylated p65 were stripped 
away, it would not bind the C-18 resin in the subsequent purification step due to its larger 
size. The denaturation of the p65 causes the bound peptide fragments to be released into 
the solution. The peptides would then be purified by a C-18 spin column and analyzed by 
LC ESI-MS. A control sample of a complete Endoproteinase AspN LSF DNA binding 
digestion would also be analyzed by LC ESI-MS. Together, the combined 
chromatograms and mass to charge ratios resulting from the three LC ESI-MS 
experiments would show a complete picture of the location of the individual peptide 
fragments throughout the assay. Based on this information, one would be able to 
determine the specific LSF DNA binding domain peptides responsible for binding p65. 
Though the assay hasn’t been performed, I would expect the results to be located 
between amino acids 65 and 103 in the DNA binding domain sequence based on the bead 
assay results in Figure 6. Furthermore, this amino acid region is also present in the 
pGEX1 construct’s expressed protein which binds p65. As such, it would be interesting if 
the data from the binding peptide identification assay agreed or disagreed with this result. 
If they agreed, it would suggest that the peptide sequence within the region of 65 and 103 
is most likely responsible for binding p65. If it differs, then more experiments would be 
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needed to determine the reason for the discrepancy. However, the results of both 
experiments can be confirmed with a modified version of the p65 biotinylation 
optimization ELISA. In this assay, the ELISA would be performed as previously but with 
one altercation. The peptides identified by the binding peptide identification assay could 
be synthesized and added to the assay at a higher concentration than the GST-DNA 
binding domain and made to compete for the binding site on the p65. Since this is a 
competition assay, the loss of binding of GST-DNA binding domain would be detected 
and compared to a sample where the peptides were absent. By using this assay, a binding 
curve of LSF’s binding to p65 could be generated and the function of the binding 
peptides could be confirmed. 
 
Drugability of LSF 
 
 The FTMAP server allows for protein-protein binding site predictions using the 
FTMAP algorithm and submitted protein data bank (PDB) files (Brenke et al. 2009). The 
FTMAP algorithm mimics X-ray crystallography and NMR binding site prediction 
methods by computationally generating a series of organic probe molecules and then 
docking these molecules on the submitted structure through the simulated binding of 
2000 molecular positions using rigid body docking (Brenke et al. 2009). The position of 
the probe molecules is refined through energy minimization and the individual probe 
molecules are clustered together based on location (Brenke et al. 2009). The average free 
energy of the clusters is then ranked for comparison (Brenke et al. 2009). Clustering of 
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probe molecules is achieved by selecting the probe molecule with the lowest free energy 
and then clustering all probe molecules in a 3 angstrom radius (Brenke et al. 2009). The 
clusters with the lowest free energy of binding are considered to be more favorable 
protein-protein binding sites (Brenke et al. 2009).  
I used the FTMAP server to analyze a LSF DNA binding domain homology 
structure created by Chetanya Pandya and based on the homology modeling and fold 
recognition data from Kokoszynska et al. (2008). Twelve clusters were generated from 
the FTMAP server and were numerically ranked based on their free energy of binding. 
Cluster 1 had the lowest free energy of binding and is located near amino acids 29, 42. 
134, 135, 183, and 185 of the homology model’s amino acid sequence. Cluster 2 is 
located near amino acids 17, 19, 21, 22, 23, 24, 33, 34, 36, 44, and 191. Cluster 3 is 
located near amino acids 134, 135, 136, 138, 183, and 184. Cluster 4 is located near 
amino acids 6, 8, 14, 16, 34, 39, and 179. Cluster 5 is located near amino acids 100, 121, 
124, 130, and 131. Cluster 6 is located near amino acids 16, 19, 21, and 34. Cluster 7 is 
located near amino acids 5, 6, 67, 69, 73, 82, 156, and 178. Cluster 8 is located near 6, 7, 
8, 156, 176, and 178. Cluster 9 is located near amino acids 54 and 161. Cluster 10 is 
located near amino acids 42, 44, 128, and 130. Cluster 11 is located near amino acids 26, 
39, 71, 72, 139, 140, 150, 182, and 194. Cluster 12 is located near amino acids 5, 6, 71, 
73, 178, and 180. It is important to consider whether any of the clusters exist in the 
regions of the sequence responsible for DNA binding since inhibitor design targeting the 
site may lead to a decrease in DNA binding. Dr. Barbara Ludeke, Christina Hao, and 
Steven Kim have mapped the proposed LSF DNA binding sites on the DNA binding 
50 
 
domain homology model based on the effects of point mutations on LSF DNA binding in 
electrophoretic mobility shift assays. Based on her analysis, the proposed DNA binding 
sites of LSF are amino acids 194, 199, 202, 205, 224, 236, 241, 244, 245, and 246. Only 
cluster 11 contains a proposed DNA binding site at amino acid 194. These results show 
that a range of potential target sites can be utilized for inhibitors thus increasing the 
drugability of LSF. 
 
Conclusion 
 
 While the protein-protein binding site(s) of LSF wasn’t definitively localized to a 
specific small stretch of the LSF sequence, significant progress was made. I found that 
both YY1 and p65 bind the DNA binding domain of LSF and that this interaction most 
likely takes place between amino acids 65 and 103. I also designed and provided 
preliminary optimization data for an assay to identify the specific binding sequence for 
the binding of LSF to p65. This assay makes use of protease digestions, p65 mediated 
peptide capture, and peptide detection using LC ESI-MS. This assay can easily be 
converted to use with YY1 as well. In this case, YY1 would need to be biotinylated and 
bound to streptavidin beads but the basic approach is the same. When this assay is 
completed, I’m confident that the specific LSF sequences required to bind p65 and YY1 
will be identified.   
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a. 
Figure 1. LSF construct information. a) Overlapping LSF DNA constructs and 
projected coded LSF sequences. The cDNA sizes are as follows: pGEX1 540bp; 
pGEX2 450bp; pGEX3 342bp; pGEX4 360bp; DNA binding domain 582bp; SAM 
domain 183bp. The pGEX1 and pGEX2 constructs overlap between the 169th amino 
acid and the 180th amino acid of the LSF sequence. This sequence range is also shared 
by the LSF DNA Binding Domain construct as well as parts of the pGEX1 and pGEX2 
constructs between the 65th amino acid and the 259th amino acid of the LSF DNA 
sequence. The pGEX3 construct contains the SAM construct as well as regions on the 
5’ and 3’ side of the construct. The ubiquitin-like domain was not independently made 
into a construct as the DNA Binding Domain and SAM domain but it is represented by 
the pGEX4 construct.  
LSF Full Length - 502 aa N- -C 
pGEX1– 180 aa 1 180 
pGEX2 - 151aa 169 319 
pGEX3 - 115aa 306 420 
pGEX4 - 120aa 383 502 
DNA Binding Domain - 
195 aa 65 259 326  SAM-63aa 
 
388 
Ubiquitin-like 502 
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b. 
Figure 1. LSF construct information. b) Amino acid sequence of LSF with domain 
information and overlapping regions in FASTA format. Domain information is 
represented as predicted in Kokoszynska et al. The sequence is represented from the 
N-terminal region to the C-terminal.  
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Figure 2. Secondary structure of YY1. Ribbon representation of YY1’s secondary 
structure from Structure of YY1 Bound to the Adeno-associated Virus Initiator by 
Houbaviy et al, 1996 (PDB ID: 1UBD) binding a 20 base pair oligonucleotide 
(hidden in figure). Looped regions are in green, α-helices are in red, and β-turns are in 
yellow. The N-terminal of the protein is indicated by the black star. 
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Figure 3. Crystal structure of p65’s rel homology domain. Ribbon representation 
of the rel homology domain as shown in Structure of NF-kB 50/p65 Heterodimer 
Bound to the PRDII DNA Element from the Interferon-Beta Promoter by  Escalante et 
al, 2002 (PDB ID: 2I9T). The black star indicates the N-terminus of the domain. The 
structure in blue is the DNA binding domain which is separated by a small linker 
region from the dimerization domain shown in red. The C-terminal transactivation 
domain is not shown as it was not included in the crystal structure. 
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Figure 4. Characterization of GST-LSF fusion proteins by SDS-PAGE. Solubilized 
GST-fusion proteins were mixed with SDS sample buffer and loaded on a 
discontinuous 10% SDS-PAGE gel. The molecular weight ladder used was Precision 
Plus Prestained Ladder from Bio-Rad. Predicted molecular weights for protein species 
are GST-pGEX1: 45.8 kDa; GST-pGEX2: 42.5 kDa; GST-pGEX3: 38.5 kDa; GST-
pGEX4: 39.2 kDa; GST-DBD: 47.3 kDa; GST-SAM: 32.8 kDa and GST-LSF: 81.4 
kDa. DBD stands for LSF’s DNA Binding Domain. 500ng of protein were loaded for 
each well. 
56 
 
  
Figure 5. Binding assay of LSF with YY1. Mammalian U2OS cell extracts were 
incubated with GST-LSF fusion proteins on glutathione beads overnight at 4˚C. 
Resulting protein complexes were eluted from the binding assay and electrophoresed 
through on a 10% SDS-PAGE gel. The gel was then immunoblotted with α-YY1. The 
molecular weight of YY1 is approximately 58 kDa. YY1 binding occurs to the proteins 
encoded by the pGEX1 and pGEX2 constructs but primarily with the pGEX4 encoded 
protein. The pGEX4 construct codes for the ubiquitin-like domain of LSF. DBD stands 
for the DNA binding domain of LSF. GST corresponds to empty pGEX-5x-1 vector 
and encodes only GST protein. The amino acid range of the encoded proteins for the 
fusion constructs are as follows: LSF 1-502; pGEX1 1-180; pGEX2 169-319; pGEX3 
306-420; pGEX4 383-502; DBD 65-259; SAM 326-388. 
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Figure 6. Binding assay of LSF with p65. Mammalian U2OS cell extracts were 
incubated with GST-LSF fusion proteins on glutathione beads overnight at 4˚C. Protein 
complexes were eluted from the binding assay and loaded on a 10% SDS-PAGE gel. 
The gel was then transferred to a PVDF membrane and blotted with α-p65. The 
molecular weight of p65 is 65 kDa. The binding assay results in a doublet for p65 where 
the lower band is a degradation product; both bands have been indicated on the blot 
with arrows. Binding occurs at the pGEX1 and pGEX2 constructs but primarily at the 
pGEX4 construct. The pGEX4 construct is responsible for expressing the ubiquitin-like 
domain of LSF. DBD stands for the DNA binding domain of LSF. GST corresponds to 
empty pGEX-5x-1 vector and encodes only GST protein. The amino acid range of the 
encoded proteins for the fusion constructs are as follows: LSF 1-503; pGEX1 1-180; 
pGEX2 169-319; pGEX3 306-420; pGEX4 383-503; DBD 65-259; SAM 326-388. 
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Figure 7. Binding assay of LSF with YY1 in the presence of phosphatase 
inhibitors. U2OS cell extracts were treated with phosphatase inhibitors prior to 
incubation with immobilized GST-fusion proteins. Protein complexes were eluted from 
the glutathione Sepharose beads with reduced glutathione and loaded on a SDS-PAGE 
gel. The gel was transferred to a PVDF membrane and probed with α-YY1. The 
molecular weight of YY1 is approximately 58 kDa. Blot shows binding of YY1 to the 
pGEX1 construct as well as the DNA Binding Domain of LSF. 
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Figure 8. Binding assay of LSF with p65 in the presence of phosphatase inhibitors. 
U2OS cell extracts were treated with phosphatase inhibitors prior to incubation with 
immobilized GST-fusion proteins. Protein complexes were eluted from the glutathione 
Sepharose beads with reduced glutathione and loaded on a SDS-PAGE gel. The gel was 
transferred to a PVDF membrane and probed with α-p65. The molecular weight of p65 
is 65 kDa. Blot shows binding of p65 to the pGEX1 construct as well as the DNA 
Binding Domain of LSF. 
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Figure 9. Two bands results from p65 due to bacterial protease bound to the 
glutathione resin. Lysed and solubilized BL21 T7 Express lysY/Iq competent E. coli 
extracts were incubated with glutathione Sepharose beads for 30 minutes at room 
temperature in order to mimic the conditions of the GST-LSF binding assay. The beads 
were then washed three times with sterile 1xPBS before being incubuated with 300 µL 
of U2OS cell extracts for 1 hour at 4°C. The beads were then centrifuged and the 
supernatant was analyzed on a 10% SDS-PAGE gel. A western blot was performed and 
the membrane was blotted with α-p65. The lower molecular weight band shows that the 
doublet is due to a potential bacterial protease non-specifically bound to the bead resin 
as the band is absent from the input control. 
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Figure 10. Factor Xa reaction optimization. GST-DNA binding domain fusion 
protein was cleaved with Factor Xa protease under various conditions. GST-DNA 
binding domain protein was captured on glutathione sepharose beads prior to digestion. 
For samples where digestion of the GST protein was performed in solution, the GST-
DNA binding domain protein was first eluted with 50 mM Tris-HCl pH 8.0, 10 mM 
reduced glutathione for 5 minutes at room temperature. The  samples were mixed with 
SDS-sample buffer, and analyzed on a 15% SDS-polyacrylamide gel with Coomassie 
Brilliant Blue. The protein band for GST-DNA binding domain is 47 kDa while the 
protein band for the DNA binding domain is about 13 kDa. Bead digestion with 1 ng/µL 
of Factor Xa for 2 hours at 37°C is the most optimal reaction condition. 
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Figure 11. ExPASy peptide cutter predicts cleavage sites for Endoproteinase 
AspN in the LSF DNA binding domain sequence. The LSF DNA binding domain 
amino acid sequence was submitted to the ExPASy peptide cutter tool. The program 
predicted 11 cleavage sites for Endoproteinase AspN with an average size of  21 amino 
acids for the peptide fragments. The peptide fragment map was used to predict the 
peptide fragments and Endoproteinase AspN cleavage sites for the binding peptide 
identification assay.  
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Figure 12. Endoproteinase AspN digests denatured DNA binding domain and 
lysozyme but not native protein. 1 µg/µL of Endoproteinase AspN was incubated in a 
10uL solution containing 50 mM Tris-HCl pH 8.0 with  2.5 mM ZnSO4 and 1 µg of 
LSF DNA binding domain or lysozyme for 16 hours at 37°C. For denatured samples, 
the DNA binding domain or lysozyme was first denatured in 6 M guanidium-HCl and 
then subsequently diluted to 2 M guanidium-HCl prior to digestion. The samples were 
analyzed on a denaturing polyacrylamide gel with Coomassie Brilliant Blue stain. The 
warping of the gel is due to the guanidium-HCl present in the denatured samples. 70% 
formic acid successfully cleaves lysozyme and DNA binding domain and 
Endoproteinase AspN cleaves denatured DNA binding domain and lysozyme as 
indicated by the absence of a protein band at 15 kDa. 
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Figure 13. HPLC Chromatogram of LSF DNA binding domain peptide fragments. 
Chromatogram is representative of peptide peaks eluted from a reverse-phase HPLC 
column. The x-axis is in minutes. Denatured LSF DNA binding domain was digested 
by Endoproteinase AspN and purified on a C-18 spin column. The peptides were eluted 
from the spin column using a 1:1 solution of acetonitrile and water before being 
transferred to Dr. Norman Lee of the Chemical Instrumentation Center (Boston 
University) and loaded on a HPLC column. The figure shows that peptides produced 
from the binding peptide identification assay can be analyzed by HPLC coupled ESI-
MS. 
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Peptide Size (daltons) Chromatogram peak 
(minutes) 
Position in LSF 
DBD sequence (aa) 
3300 0.92 149-178 
990 1.09, 50.63 185-194 
2310 24.25 61-81 
1980 24.25, 50.63 18-35 
1650 50.63 82-96 
1870 26.18, 26.79, 28.5 1-17 
2750 50.63 36-60 
1760 50.63 97-112 
  
Table 1. Peptide fragments assigned to HPLC chromatogram peaks. LSF DNA 
binding domain peptide fragments obtained from mass to charge ratios from ESI-MS 
and their corresponding time signatures on the HPLC chromatogram displayed in 
Figure 13. Peptide fragment sizes were determined from the mass to charge ratios 
taken from the ESI-MS data in conjunction with the Endoproteinase AspN peptide 
fragment prediction map in Figure 11.  The position in LSF DBD sequence refers to 
the peptide fragment positions in the sequence presented in Figure 11. 
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Figure 14. Coomasie blue analysis of p65 sample provided by Dr. Trevor Siggers 
on a 10% polyacrylamide denaturing gel. p65 protein obtained from Dr. Trevor 
Siggers of Boston University was mixed with SDS-sample buffer and analyzed by 
denaturing polyacrylamide gel electrophoresis with Coomassie Brilliant Blue staining. 
The protein preparation is only partially purified, with three other major protein bands 
besides the band correspond to p65; multiple minor bands are also present. This 
protein is used in all subsequent p65 biotinylation experiments. 
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Figure 15. LSF-DNA binding domain binds p65. a). Bacterial expressed 
recombinant p65 protein was biotinylated and then incubated with GST-LSF DNA 
binding domain immobilized on glutathione sepharose beads. The bound proteins were 
eluted with reduced glutathione and separated on a denaturing polyacrylamide gel 
before being transferred to a PVDF membrane. The protein bands within the black 
rectangle belong to p65.The membrane was immunoblotted with α-p65. The figure 
shows  that LSF DNA binding domain binds both biotinylated and non-biotinylated 
p65 and that the biotinylated p65 is active. 
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Figure 15. p65 bound to GST-LSF DNA binding domain is biotinylated. b) 
Bacterially expressed recombinant p65 protein was biotinylated and then incubated with 
GST-LSF DNA binding domain immobilized on glutathione sepharose beads. The 
bound proteins were eluted with reduced glutathione and separated on a denaturing 
polyacrylamide gel before being transferred to a PVDF membrane. The membrane was 
immunoblotted with streptavidin-HRP conjugate. The protein bands in the black 
rectangle represent biotinylated p65. This figure shows that the p65 bound to the GST-
LSF DNA binding domain is biotinylated, however, when compared to Figure 15a, the 
amount of active p65 biotinylated is a small fraction of the overall p65 sample. 
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Figure 16. ELISA background signal is due to α-GST and GST-DNA binding 
domain. An ELISA was performed with 100 µL of 10 ng/µL biotinylated p65 captured 
on an immunoabsorbant 96-well plate coated with 1 pmol per well of avidin. 50 µL per 
well of 10 nM and 100 nM GST-DNA binding domain was bound to the p65 and 
detected with 100 µL of 0.4 ng/µL α-GST rabbit polyclonal. 100 µL of a 1:4,000 
dilution of α-rabbit IgG-HRP was used to detect the α-GST. The color change of 50 µL 
TMB was quenched with 50 µL H2SO4 and measured at 450 nm on a plate reader. One 
out controls were used for each component. The figure shows that the majority of the 
signal is due to background from the GST-DNA binding domain and the α-GST 
components.  
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Figure 17. Multiple biotinylation conditions  in ELISA. p65 was biotinylated at two 
times and one half of the suggested biotinylation reagent concentration of 20 fold M 
excess. 100 µL of 10 ng/µL biotinylated p65 was captured on an immunoabsorbant 
96-well plate coated with 1 pmol per well of avidin. 50 µL per well of 100 nM GST-
DNA binding domain was bound to the p65 and detected with 100 µL of 0.4 ng/mL α-
GST rabbit polyclonal. Dilution samples of 0.4 µg/mL and 0.4 pg/mL α-GST were 
also used. 100 µL of a 1:15,000 α-rabbit IgG-HRP dilution was used to detect the α-
GST. 1:5,000 and 1:40,000 dilutions of α-rabbit IgG-HRP were also tested as samples. 
The color change of 50 µL TMB was quenched with 50 µL H2SO4 and measured at 
450 nm on a plate reader. The results show that 0.4 ng/mL of α-GST and 1:15,000 of 
α-rabbit IgG-HRP are suitable dilutions for future ELISAs.  
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Figure 18. Biotinylated p65 dose response curve ELISA. 5 µg, 1 µg, and 0.2 µg of 
biotinylated p65 from different biotinylation reagent concentrations were added to 
plates coated with 1 pmol per well of avidin. 50 µL of 10 nM GST-DNA binding 
domain was bound to the biotinylated p65 and detected with 100 µL 0.4 ng/mL α-GST. 
100 µL of a 1:15,000 α-rabbit IgG-HRP dilution was used to detect the α-GST. The 
color change of 50 µL TMB was quenched with 50 µL H2SO4 and measured at 450 nm 
on a plate reader.  One out controls were used for each assay component. The figure 
suggests that the low signal is due to less than 0.2 µg of biotinylated p65 being captured 
on the plate surface.  
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Figure 19. α-p65 dilution curve ELISA. 100 µL of different dilution of α-p65 were 
plated on an immunoabsorbant 96-well plate blocked with 1% BSA in 1xPBST. 100 
µL of a 1:15,000 α-rabbit IgG-HRP dilution was used to detect the α-p65. A 1:5,000 
dilution of α-rabbit IgG-HRP was used as a positive control. The non-specific binding 
of the p65 antibody was analyzed and it was determined that 1:3,000 was a suitable 
dilution for future studies. 
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Figure 20. 100 pmol avidin-coating per well and DNA binding domain-p65 coupled 
biotinylation results in higher signal.  Equal amounts of  p65 and LSF DNA binding 
domain were bound together and biotinylated with a 20 fold, 100 fold, and 4 fold M 
excess biotinylation reagent concentration. 10 ng/µL biotinylated p65 was then captured 
on an immunoabsorbant 96-well plate coated with 100 pmol per well of avidin. 50 µL of 
10 nM GST-DNA binding domain was bound to the biotinylated p65 and detected with 
100 µL 0.4 ng/mL α-GST. A 1:3,000 dilution of α-p65 was used to detect the total 
amount of biotinylated p65. 100 µL of a 1:15,000 α-rabbit IgG-HRP dilution was used 
to detect the α-GST and the α-p65. One out controls were used for each assay 
component. The low signal for the α-p65 experimental samples suggests that not enough 
antibody is present to give a suitable signal over background. 
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Figure 21. Pilot ELISA of different blocking conditions. 200 µL of 1% BSA, 5% 
BSA, 5% sucrose, or 5% milk in 1xPBST was added to an immunoabsorbant 96-well 
plate. Superblock from Pierce Biotechnology was also used as a candidate blocking 
solution. After a 16 hour incubation at 4°C, 100 µL of 1:150, 1:300, or 1:1500 α-p65 
was added to plate. Non-specific binding of the p65 antibody was detected with 
1:15,000 α-rabbit IgG-HRP. The color change of 50 µL TMB was quenched with 50 µL 
H2SO4 and measured at 450 nm on a plate reader. The results suggest that Superblock is 
the most suitable blocking solution for α-p65.  
75 
 
   
Figure 22. GST contamination from DNA binding domain-p65 coupled 
biotinylation results in high background signal. Equal amounts of  p65 and LSF 
DNA binding domain were bound together and biotinylated with a 20 fold, 100 fold, 
and 4 fold M excess biotinylation reagent concentration. 10 ng/µL biotinylated p65 
was then captured on an immunoabsorbant 96-well plate coated with 100 pmol per 
well of avidin. 50 µL of 10 nM GST-DNA binding domain was bound to the 
biotinylated p65 and detected with 100 µL 0.4 ng/mL α-GST. A 1:150 dilution of α-
p65 was used to detect the total amount of biotinylated p65. 100 µL of a 1:15,000 α-
rabbit IgG-HRP dilution was used to detect the α-GST and the α-p65. The high 
background signal in the biotinylated p65 α-GST control suggests that the observed 
signal for the GST-DNA binding domain bound to p65 is due to GST contamination of 
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